Immunogenicity refers to the ability of a medicinal product, particularly a therapeutic protein, to elicit an immune response. In drug development, this concerns the probability, nature and clinical significance of an immune reaction directed against the medicinal product. The assessment combines product characteristics, nonclinical findings, appropriate bioanalytical methods and clinical observations into an ongoing benefit-risk assessment.
Immune response and possible clinical consequences
Therapeutic proteins can elicit anti-drug antibodies, or ADA. Such antibodies may remain without any recognizable clinical consequence, alter pharmacokinetics or reduce the expected effect. Neutralizing antibodies are a functionally relevant subgroup of ADA: they impair the biological activity of the medicinal product or its binding to the target molecule. Detection of ADA alone therefore demonstrates neither a loss of efficacy nor a safety problem; what is decisive is the relationship to exposure, pharmacodynamic parameters, efficacy and adverse events.
The clinical significance depends, among other things, on titer, persistence, timing of antibody formation, dose, treatment duration and concomitant medication. For some products, the immune response may contribute to infusion or hypersensitivity reactions. For others, it primarily alters clearance and thus medicinal product exposure. Cross-reactive antibodies against endogenous proteins may also be relevant. Immunogenicity is therefore not only an issue at the time of marketing authorization, but also forms part of the planning of study populations, sample collection and safety monitoring.
Three-tiered bioanalytical testing strategy
The assessment usually follows a three-tiered scheme. First, a screening assay is used to identify samples with possible ADA reactivity as sensitively as possible. Reactive samples are examined in a confirmatory assay for their specificity to the medicinal product. Only then does characterization follow, for example by titer and temporal course; where necessary, a neutralization assay is used to investigate whether the antibodies inhibit the biological function of the product. Each tier requires predefined acceptance criteria and appropriate validation.
Methodological interfering factors form part of the interpretation. Circulating medicinal product may bind ADA and affect their measurability, while pre-existing antibodies, matrix effects or nonspecific binding may lead to false-positive signals. Sample time points are therefore adapted to dosing, expected pharmacokinetics and the clinical question. The EMA recommends a risk-based strategy that takes into account the characteristics of the product as well as the possibility and consequences of an immune response. Results must be combined with clinical data and not assessed in isolation.
Distinction from allergy and immunotoxicity
Immunogenicity is the umbrella term for an immune response elicited by the medicinal product and includes, in particular, the formation of ADA. An allergy or hypersensitivity reaction, by contrast, is a clinical event with symptoms that may occur immediately or after a delay and is not necessarily explained by detectable ADA. Allergic reactions therefore form part of the clinical safety assessment, whereas immunogenicity analytics investigate the presence and characteristics of a response directed against the medicinal product.
Immunotoxicity refers to harmful changes in the function or structure of the immune system caused by a substance. It may involve, for example, immunosuppression, dysregulation or enhanced immune reactions. It must be distinguished from immunogenicity: the question “does the organism produce antibodies against the medicinal product?” differs from the question “does the medicinal product impair the immune system?”. Nonclinical immunotoxicity studies and clinical ADA programs therefore serve different purposes.
Relevance for clinical trials
An immunogenicity program must be integrated into the clinical development program at an early stage. The sample plan, storage, bioanalytics, data linkage and analysis plan must be designed so that ADA results can be assigned to the relevant medicinal product exposures, efficacy endpoints and safety events. Consistent assay versioning, traceable decisions on cut points and the predefined assessment of neutralizing antibodies are particularly important. Authorities consider not only the rate of positive samples, but also the clinical significance and risk management.
Full-service CROs such as Mediconomics support the planning of sample time points, the coordination of qualified bioanalytics and the integration of results into data management and statistics. The scope of services also includes protocol sections on immunogenicity, coordination of safety processes, medical assessment of abnormal findings, as well as medical writing for clinical study reports and regulatory documents.
Frequently Asked Questions (FAQ)
Does a positive ADA finding mean that the medicinal product does not work?
No. A positive finding must be assessed together with titer, persistence, medicinal product concentration, efficacy and safety. Some ADA remain without any recognizable clinical consequence, while others may alter exposure or effect.
Why are neutralizing antibodies not always measured immediately?
A neutralization assay is a functional characterization and is generally used for confirmed ADA-positive samples or according to a predefined algorithm. The three-tiered approach combines sensitive detection with a specific and clinically relevant classification.
Can immunogenicity be reliably predicted from animal studies?
Only to a limited extent. Animal immune responses may be relevant for the interpretation of nonclinical findings, but because of species differences they do not reliably predict immunogenicity in humans. Clinical assessment remains decisive.
Regulatory references
- EMA, Guideline on Immunogenicity Assessment of Therapeutic Proteins – describes a risk-based assessment and the integration of clinical and bioanalytical data.
- ICH S6(R1), Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals – places the nonclinical safety assessment of biotechnology-derived medicinal products in context.
- ICH M3(R2), Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals – identifies immunotoxicity as an area to be assessed on a case-by-case basis.